Two Pilot Clinical Studies Show Promising Results: AHCC Mushroom Extract May Eradicate Recurrent HPV Infections in Women
North American Precis Syndicate
Scientists have found a way to use a mushroom extract to help women infected with HPV. (NAPS)
(NAPSI)—Two clinical studies conducted at McGovern Medical
School at The
University of Texas Health Science Center at Houston (UTHealth)
showed that AHCC® mushroom extract can clear infections in women
with recurrent human papillomavirus (HPV). Results
of the most recent study were presented at the 14th International
Conference of the Society for Integrative Oncology held in Chicago on
November 12−14, 2017.
The objective of the two studies was to determine whether AHCC could
eradicate an HPV infection in women at two different daily supplementation
amounts (AHCC 1 gram or AHCC 3 grams) and to assess the necessary duration
for AHCC therapy to be effective.
The first pilot study enrolled 10 women with persistent high-risk HPV
infection taking 3 grams of AHCC once daily from five weeks up to six months.
Half of the subjects who stayed on the protocol for four months showed a
complete eradication of the HPV virus. "Eradication" means that they cleared
the infection by the end of the supplementation period and remained
infection-free when tested two months post-supplementation.
The second study, which looked at the efficacy of AHCC at the 1-gram dose,
tracked 10 women with persistent, high-risk HPV infections for up to a period
of eight months. The study observed that four of nine patients experienced
eradication of the HPV infection by the end of the study period. One patient
was withdrawn from the study due to an unanticipated pregnancy and
noncompliance with study protocol.
On average, it took the responders in the AHCC 1-gram study longer to
eradicate the HPV infection compared to duration of supplementation observed
in the AHCC 3-gram study. These findings suggest that AHCC daily
supplementation successfully modulates the host immune system to effectively
eradicate persistent, high-risk HPV infections. Since the AHCC 3-gram
supplementation achieved results in shorter duration, it is the recommended
supplementation dose for future evaluation and use for this research.
The study was conducted by Dr. Judith Smith, the Director of Women's
Health Integrative Medicine Research Program in the Department of Obstetrics,
Gynecology & Reproductive Sciences at McGovern Medical
School at the University of Texas.
AHCC is a compound derived from cultured mycelia of Japanese lentinula edodes
mushrooms. Standardized to acylated alpha-1,4-glucans, AHCC has been the subject of over 60
Medline-indexed and more than 20 human studies. Clinical research has shown
that AHCC increases the number and activity of natural killer (NK) cells, dendritic cells and specific cytokines that help the body
fight off infections and block growth of abnormal cells. The compound's mode
of action has been shown to be the stimulation of TLR-2 and TLR-4 receptors
in the gut and its function as a prebiotic,
nourishing the beneficial colonic and intestinal bacteria. AHCC has been
widely used in Japan for
over 30 years and in the U.S.
for more than 15 years. It is offered as a dietary supplement and is also
available in higher potency as a prescription medical food.
AHCC Research Association
The mission of the AHCC Research Association is to increase public
awareness of AHCC in integrative medicine, educate consumers and doctors on AHCC's preventative and therapeutic benefits, and support
research studies on AHCC. For more information, please visit www.ahccresearch.org.
The human papillomavirus (HPV) is a virus that
has been detected in more than 99 percent of cervical cancer patients.
According to the Centers for Disease Control and Prevention, several other
cancers are related to HPV, including 95 percent of anal cancers, 60 percent
of oropharyngeal cancers, 65 percent of vaginal
cancers, 50 percent of vulvar cancers and 35
percent of penile cancers.
While most HPV infections are self-limiting and resolve without causing
any symptoms, there is currently no effective treatment for those that
persist and that the body's innate immune system cannot clear. According to
Dr. Judith Smith, "We test women for HPV, and if they have a persistent
infection, there is nothing we can do for them except watch and wait. With
AHCC, we may be able to eliminate that terrible limbo when a woman is in
between HPV infection and a possible cancer diagnosis."
"HPV is associated with many life-threatening cancers," said Dr. Smith. "What
we need is a safe, effective treatment for HPV before the cancer occurs."
About Dr. Smith
Dr. Smith's research focus is on the safe and effective use of nutritional
and herbal supplements with pharmacologic modalities as they relate to women's
health. Her current research involves cancer eradication of high-risk HPV
infections in women with persistent HPV infection.
For more information, please contact the AHCC Research Association at email@example.com.
On the Net:North American Precis Syndicate, Inc.(NAPSI)